Company has definitely turned the corner on the margins front.What impressed me was the 30%+ kind of EBITDA they make in Pharma division.LSI business also showed a strong margin performance.Revenue growth should pick up in coming quarters.Moreover,JLS got 2 USFDA approvals in Q1,and expects some approvals every quarter.Radiopharma is another interesting segment.
Some news today: http://www.bseindia.com/xml-data/corpfiling/AttachLive/73E8CC0D_91C6_4FBF_8AAB_DF7FEB11ADC6_122247.pdf
Disc.: Invested.One of my top holdings
| Subscribe To Our Free Newsletter |
